TAT(SZ:002433)2020-06-19 16:00Financial Performance - The company's operating revenue for 2019 was ¥4,013,155,237.25, representing a 21.05% increase compared to ¥3,315,297,745.99 in 2018[19]. - The net profit attributable to shareholders for 2019 was ¥96,093,939.63, a decrease of 64.53% from ¥270,891,715.00 in 2018[19]. - The net profit after deducting non-recurring gains and losses was ¥35,396,243.53, down 9.61% from ¥39,159,358.51 in 2018[19]. - The net cash flow from operating activities increased by 210.56% to ¥336,247,215.89 from ¥108,271,087.96 in 2018[19]. - The total assets at the end of 2019 were ¥8,804,983,315.85, a 1.50% increase from ¥8,675,109,256.08 at the end of 2018[19]. - The net assets attributable to shareholders at the end of 2019 were ¥5,230,371,954.78, reflecting a 0.83% increase from ¥5,187,447,293.02 at the end of 2018[19]. - The basic earnings per share for 2019 were ¥0.13, down 62.86% from ¥0.35 in 2018[19]. - The diluted earnings per share for 2019 were also ¥0.13, a decrease of 62.86% from ¥0.35 in 2018[19]. - The weighted average return on equity for 2019 was 1.84%, down from 5.36% in 2018[19]. - The company achieved total revenue of ¥4,013,155,237.25, an increase of 21.05% compared to the previous year[42]. - The net profit attributable to shareholders decreased by 64.53% to ¥96,093,939.63[42]. Cash Dividends - The company reported a cash dividend of 0.151 yuan per 10 shares, based on a total of 766,773,200 shares[6]. - For the 2019 fiscal year, the company plans to distribute a cash dividend of CNY 0.151 per 10 shares, amounting to CNY 11.58 million, pending shareholder approval[97]. - The cash dividend distribution plan for 2019 proposes a cash dividend of 0.151 CNY per 10 shares, totaling 11,578,275.32 CNY, which represents 12.05% of the net profit[101]. - The cash dividend accounted for 100% of the total profit distribution, adhering to the minimum requirement of 20% for cash dividends during significant capital expenditures[99][104]. - The company has committed to distributing at least 30% of the average distributable profit over the past three years, barring significant investment plans[103]. Business Operations - The company has maintained its main business operations without any changes since its listing[18]. - The company has not experienced any changes in its controlling shareholder since its establishment[18]. - The company’s registered address is located in the Jin Yuan Industrial Zone, Shantou City, Guangdong Province[14]. - The company’s stock is listed on the Shenzhen Stock Exchange under the code 002433[14]. - The company has a dedicated investor relations team to handle inquiries and provide information to shareholders[15]. - The company emphasizes the importance of risk awareness in its future development statements[6]. - The company has established a comprehensive disclosure system through various media outlets, including the Securities Times and China Securities Journal[16]. Product Development and Market Strategy - The company reported a total of nearly 400 drug approval numbers and 25 exclusive products, establishing a diverse product portfolio[28]. - The company has developed 25 unique domestic products, including the patented Qilin Pill, which is the only approved treatment for male infertility and female infertility in China[36]. - The company is focusing on the reproductive health sector, with a potential market size of 10 billion RMB for infertility treatments in China[36]. - The company is actively expanding its internet hospital business and optimizing its strategic and operational layout[30]. - The company is focusing on expanding its market presence through various sales channels, including self-operated, agency, and e-commerce[42]. - The company is committed to environmental protection and has improved its management level in compliance with national regulations[45]. Research and Development - The company is actively involved in R&D, collaborating with institutions on projects like the secondary development of the traditional Chinese medicine 麒麟丸[43]. - The company has invested in R&D, resulting in five invention patents and two pending applications, collaborating with several prestigious research institutions[138]. - The company is conducting clinical trials for its key product, Qilin Wan, to treat infertility combined with low ovarian reserve[67]. - The company has initiated collaborations for the development of new drugs and therapies, including studies on Qilin Wan for additional indications[67]. Corporate Governance - The company has established a comprehensive corporate governance structure, including a board of directors and various specialized committees[132]. - The company emphasizes the protection of shareholder and creditor rights, ensuring timely disclosure of significant information[132]. - The company has implemented a reasonable compensation and performance evaluation system to enhance employee motivation[134]. - The company has established a complete organizational structure, with independent operation of the shareholders' meeting, board of directors, and supervisory board[186]. - The company has committed to balancing the interests of shareholders, employees, and society, promoting sustainable and healthy development[183]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 52,048, down from 55,396 at the end of the previous month[147]. - The largest shareholder, Taiantang Group Co., Ltd., held 26.17% of the shares, totaling 200,700,110 shares, with a decrease of 50,889 shares during the reporting period[149]. - The second-largest shareholder, Ou Mingmei, held 6.90% of the shares, totaling 52,900,000 shares, with no change during the reporting period[149]. - The actual controller, Ke Shuqian, indirectly holds shares through Taiantang Group Co., Ltd., which owns 69.35% of the company[153]. - The company did not engage in any repurchase transactions among the top 10 common shareholders during the reporting period[150]. Employee and Social Responsibility - Employee representation includes 31% female employees and approximately 2% disabled employees, with a focus on creating a safe and healthy work environment[134]. - The company has been recognized as a "Contract-abiding and Trustworthy Unit" by local authorities for several consecutive years[133]. - The company actively engages in social responsibility initiatives, contributing to community service and public welfare[140]. - The company has increased its tax contributions to the state and local governments year by year, becoming a major taxpayer in its region[138]. Financial Management - The company has independent financial management and internal audit departments, with a separate accounting system and independent bank accounts[186]. - The company has maintained its current accounting firm, Zhongxinghua Accounting Firm, for three consecutive years, with an audit fee of CNY 2,000,000[111]. - The company has implemented changes in accounting policies and estimates in accordance with new financial reporting standards, affecting the presentation of receivables and payables[106]. - The company reported no significant accounting errors requiring retrospective restatement during the reporting period[109].